Evidence map›Paper›PMID 41699136›Full record

ArticleMycopathologia2026

Fungaemia Caused by the Rare Yeast Starmerella sorbosivorans: A Case Report with Identification via Molecular Phylogenetic Analysis and MALDI-TOF MS.

Shunkichi Ikegaki, Yuka Nagatsuka, Sayaka Ban, Daiki Kano, Goh Ohji, Hiroshi Yamamoto, Kentaro Iwata, Yuhki Sato

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shunkichi Ikegaki *Division of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan. ikegaki@gmail.com.ORCID http://orcid.org/0000-0002-0411-1061
Yuka Nagatsuka *Department of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Hiroshima, Japan.
Sayaka BanMedical Mycology Research Center, Chiba University, Chiba, Japan.
Daiki KanoDepartment of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Hiroshima, Japan.
Goh OhjiDivision of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Hiroshi YamamotoDepartment of Infection Control and Prevention, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Kentaro IwataDivision of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Yuhki SatoDepartment of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Hiroshima, Japan.

Funding

Institute for Fermentation, Osaka G-2022-3-023
6 · The paper itself

Abstract

Invasive yeast infections are associated with high mortality rates, particularly in immunocompromised patients. While most cases of fungaemia are caused by Candida species, rare yeast infections occasionally occur. Here, we present the first documented case of a Starmerella sorbosivorans (= Candida sorbosivorans, homotypic synonym) bloodstream infection in a 39 year-old man with chronic intestinal pseudo-obstruction requiring parenteral nutrition via a tunnelled central venous catheter. The patient presented with fever and was diagnosed with catheter-related bloodstream infection. Initial biochemical identification suggested S. magnoliae, but MALDI-TOF mass spectrometry (MS) failed to provide a definitive identification. Molecular phylogenetic analysis using multiple loci (18S rDNA, internal transcribed spacer [ITS] region, 26S rDNA-D1/D2, TEF1α, and RPB2), combined with proteomic analysis using MALDI-TOF MS, confirmed the isolate as S. sorbosivorans, despite a low ITS sequence similarity (91.3%) to the type strain. The patient was successfully treated with sequential administration of micafungin and liposomal amphotericin B, along with removal of the catheter. Antifungal susceptibility testing revealed low minimum inhibitory concentrations (MICs) for micafungin, amphotericin B, and voriconazole, but high MICs for fluconazole. Our findings emphasise the importance of multilocus sequence analysis for accurate species identification, especially in rare yeast infections caused by uncommon species such as S. sorbosivorans, for which conventional methods may be insufficient. However, to improve the applicability of MALDI-TOF MS in clinical settings, the reference library should be expanded to include rare and emerging yeast species.

Indexed as

Catheter-Related InfectionsFungemiaSaccharomycetalesAmphotericin BAntifungal AgentsCluster AnalysisDNA, FungalDNA, RibosomalDNA, Ribosomal SpacerEchinocandinsHumansLipopeptidesMaleMicafunginPhylogenyProteomicsAmphotericin BAntifungal AgentsDNA, FungalDNA, RibosomalDNA, Ribosomal SpacerEchinocandinsLipopeptidesMicafunginCatheter-related bloodstream infectionMALDI-TOF mass spectrometryStarmerella sorbosivorans

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.